Novavax, Inc. (NVAX)

NASDAQ: NVAX · Real-Time Price · USD
8.96
+0.09 (1.01%)
Sep 23, 2025, 10:56 AM EDT - Market open
1.01%
Market Cap1.46B
Revenue (ttm)1.08B
Net Income (ttm)422.82M
Shares Out 162.42M
EPS (ttm)2.54
PE Ratio3.52
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume913,642
Open8.90
Previous Close8.87
Day's Range8.84 - 9.04
52-Week Range5.01 - 15.22
Beta2.68
AnalystsBuy
Price Target14.29 (+59.49%)
Earnings DateNov 11, 2025

About NVAX

Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adoles... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Dec 5, 1995
Employees 952
Stock Exchange NASDAQ
Ticker Symbol NVAX
Full Company Profile

Financial Performance

In 2024, Novavax's revenue was $682.16 million, a decrease of -30.65% compared to the previous year's $983.71 million. Losses were -$187.50 million, -65.60% less than in 2023.

Financial Statements

Analyst Summary

According to 7 analysts, the average rating for NVAX stock is "Buy." The 12-month stock price target is $14.29, which is an increase of 59.49% from the latest price.

Price Target
$14.29
(59.49% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Mizuho's Jared Holz: There's not much value left in vaccine stocks

Jared Holz, Mizuho healthcare senior strategist, joins CNBC's 'Squawk on the Street' to discuss outlooks on pharmaceuticals, what new government vaccine panel recommendations mean for the stocks, and ...

Other symbols: BNTXMRNAPFE
3 days ago - CNBC Television

Novavax, Inc. (NVAX) Presents At Cantor Global Healthcare Conference 2025 Transcript

Novavax, Inc. (NASDAQ:NVAX) Cantor Global Healthcare Conference 2025 September 4, 2025 10:20 AM EDT Company Participants John Jacobs - President, CEO & Director Ruxandra Draghia-Akli - Executive VP a...

18 days ago - Seeking Alpha

Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment

GAITHERSBURG, Md. , Sept. 4, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced a milestone payment* from Takeda has been triggered by regulatory approval for Novavax's COVID-19 vaccine...

19 days ago - PRNewsWire

Novavax to Participate in the Cantor Global Healthcare Conference

GAITHERSBURG, Md. , Sept. 3, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the following upcoming investor conference: Cantor Global Healthcare Conferen...

20 days ago - PRNewsWire

Novavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.

Nuvaxovid™ is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season GAITHERSBURG, Md. , Aug. 27, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX...

26 days ago - PRNewsWire

Novavax Announces Convertible Debt Refinancing

Refinancing extends maturity of most existing debt with improved terms $225 million of convertible notes due in 2031 issued, including a ~$175 million exchange for the retirement of existing convertib...

4 weeks ago - PRNewsWire

Novavax, Inc. (NVAX) Q2 2025 Earnings Call Transcript

Novavax, Inc. (NASDAQ:NVAX) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants James Patrick Kelly - Executive VP, CFO & Treasurer John Charles Jacobs - President, CEO & ...

6 weeks ago - Seeking Alpha

Novavax beats quarterly revenue estimates on milestone payment

Novavax beat Wall Street expectations for second-quarter revenue on Wednesday, helped by a $175 million milestone payment related to U.S. approval of its COVID-19 vaccine in May.

6 weeks ago - Reuters

Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights

Total revenue of $239 million in the second quarter of 2025 Received FDA BLA approval for Nuvaxovid™, the only recombinant protein-based, non-mRNA COVID-19 vaccine available in the U.S.; approval trig...

6 weeks ago - PRNewsWire

Novavax to Report Second Quarter 2025 Financial Results on August 6, 2025

GAITHERSBURG, Md. , July 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its second quarter 2025 financial results and operational highlights at 8:30 a.m.

7 weeks ago - PRNewsWire

Novavax Shares Promising Results For Bird Flu Vaccine, Tested In Primates

Novavax, Inc. NVAX on Thursday revealed preclinical data from the H5N1 avian pandemic influenza vaccine candidate.

2 months ago - Benzinga

Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study

Peer-reviewed data shows Novavax's H5N1 vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or two-dose administration Potential for single int...

2 months ago - PRNewsWire

Novavax, Inc. (NVAX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Novavax, Inc. (NASDAQ:NVAX) Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 2:00 PM ET Company Participants James Patrick Kelly - Executive VP, CFO & Treasurer John Charles Jacob...

3 months ago - Seeking Alpha

Novavax's COVID-flu combo and standalone flu shots improve immunity in late-stage study

Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines showed strong immune responses in some patients tested in a late-stage study, the company said on Wednesday.

3 months ago - Reuters

Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial

Both vaccine candidates induced robust immune responses across all antigens tested No new safety signals were observed and both vaccine candidates were well tolerated consistent with past trials Novav...

3 months ago - PRNewsWire

Vaccine actions and policy positions under US Health Secretary Kennedy

U.S. Health Secretary Robert F. Kennedy Jr., a long-time vaccine skeptic, has been making sweeping changes to reshape U.S. regulation of vaccines, food and medicine.

Other symbols: BNTXMRNAPFE
3 months ago - Reuters

Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up

Shares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S. Health Secretary Robert F. Kennedy Jr. fired all members of an expert vaccin...

Other symbols: BNTXMRNAPFE
3 months ago - Reuters

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors.

Investors will be waiting for news on how the makeup of a reconstituted ACIP will look like.

Other symbols: BNTXMRNAPFESNY
3 months ago - Barrons

Novavax to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md. , May 29, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the following upcoming investor conferences: Jefferies Global Healthcare Confe...

4 months ago - PRNewsWire

Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli

Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating their protein-based vaccine technology. The approval positions Novavax as the o...

4 months ago - Seeking Alpha

Healthy Returns: Novavax scores narrower Covid vaccine approval after delay

The FDA approved Novavax's Covid-19 vaccine but with unusual restrictions.

4 months ago - CNBC

Top Stock Movers Now: Tesla, AutoZone, Novavax, and More

U.S. equities were down at midday, while the yield on the 10-year Treasury jumped, as the market reacted to Moody's downgrading the U.S. debt rating. The Dow Jones Industrial Average, S&P 500, and Nas...

Other symbols: AZOTSLA
4 months ago - Investopedia

Novavax Stock Rockets. FDA Finally Had Good News for the Covid-19 Vaccine Maker.

Nuvaxovid had been available under emergency use authorization but the full approval may allow it to better compete with rival vaccine makers.

4 months ago - Barrons

Novavax shares jump after long-awaited FDA approval of its COVID-19 vaccine

Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 vaccine from the U.S. health regulator, albeit with new conditions.

4 months ago - Reuters

U.S. FDA Approves BLA for Novavax's COVID-19 Vaccine

Nuvaxovid™ is the only recombinant protein-based, non-mRNA COVID-19 vaccine available in the U.S. Biologics License Application approval triggers $175 million Sanofi milestone payment, with additional...

4 months ago - PRNewsWire